October 5, 2026
GE HealthCare is making a $945 million bet on the rapidly expanding radiopharmaceutical market, agreeing to acquire privately held SOFIE Biosciences in a deal designed to strengthen its U.S. manufacturing and distribution capabilities for PET imaging drugs.
The transaction is much more than a conventional medical-device acquisition. It gives GE HealthCare access to a network built around the time-sensitive production and delivery of radioactive imaging agents, while also giving the company U.S. rights to FAPI-74, an experimental PET radiotracer being evaluated in late-stage clinical trials.
The deal is expected to close in the first half of 2027, subject to regulatory approvals and other closing conditions. Once completed, SOFIE will become part of GE HealthCare's Pharmaceutical Diagnostics, or PDx, segment.
What GE HealthCare is buying
SOFIE Biosciences is a U.S.-based contract manufacturing organization focused on radiopharmaceuticals used in PET imaging.
GE HealthCare says SOFIE has a U.S. network of 15 contract manufacturing sites operating 21 cyclotrons, together with a theranostics-focused contract development and manufacturing facility. That network gives GE HealthCare a larger presence close to the medical centers that ultimately need these short-lived products.
SOFIE is headquartered in Dulles, Virginia, and has built its business around radiopharmaceutical production, distribution and development. Its own materials describe a network designed to deliver PET products to imaging centers across the United States.
Why the manufacturing network matters
PET imaging does not work like an ordinary pharmaceutical supply chain.
Many PET radiopharmaceuticals contain radioactive isotopes that decay relatively quickly. GE HealthCare says commonly used F-18-labeled PET radiopharmaceuticals have a half-life of about 110 minutes.
That short half-life means production and delivery have to be coordinated much more tightly than with conventional medicines. A product cannot simply be manufactured in one distant location and stored for long periods.
Manufacturing capacity closer to imaging centers can therefore become an important part of patient access.
What is a radiopharmaceutical?
A radiopharmaceutical is a radioactive compound used in nuclear medicine for imaging or, in some cases, targeted treatment.
In PET imaging, a radiopharmaceutical acts as a tracer. After it is administered, the PET scanner detects signals from the radioactive material and creates images that can reveal biological activity inside the body.
This is different from a conventional X-ray or CT scan, which primarily shows anatomy. PET imaging can provide information about molecular or metabolic activity, making it useful in areas including cancer evaluation and other medical conditions.
The value of the radiopharmaceutical therefore sits alongside the scanner itself. Having advanced PET equipment is not enough if the required imaging agent cannot be manufactured and delivered reliably.
The “final mile” is the strategic prize
GE HealthCare describes the acquisition as establishing a footprint in the time-critical “final mile” of U.S. PET radiopharmaceutical supply.
That phrase is important because GE HealthCare already has a broad medical-imaging business. The acquisition adds more direct control over the manufacturing and distribution stage between radiopharmaceutical development and the imaging centers that use these products.
In other words, GE HealthCare is not simply buying another product. It is buying infrastructure.
The shorter the radioactive product's useful life, the more important manufacturing location, scheduling, logistics and delivery reliability become.
FAPI-74 adds another layer to the deal
The acquisition also gives GE HealthCare U.S. rights to FAPI-74, a fluorine-18 PET radiotracer being studied in Phase III clinical trials.
FAPI-74 targets fibroblast activation protein, or FAP, a biological target associated with cancer-associated fibroblasts in the tumor microenvironment.
SOFIE has been developing FAPI-74 and has already begun Phase III clinical studies. One trial is focused on gastroesophageal cancers, while another is focused on pancreatic ductal adenocarcinoma.
Importantly, FAPI-74 is still an investigational product. Its potential clinical applications should not be treated as established medical uses until the necessary clinical and regulatory processes are completed.
GE HealthCare already had part of the FAPI relationship
The FAPI connection between the two companies did not begin with this acquisition.
In 2023, SOFIE and GE HealthCare entered a licensing agreement covering FAPI radiotracers. Under that arrangement, GE HealthCare obtained global rights to FAPI-46 and rights outside the United States for FAPI-74, while SOFIE retained U.S. clinical-development and commercialization rights for FAPI-74.
The acquisition changes that structure by bringing the U.S. rights for FAPI-74 into GE HealthCare along with SOFIE itself.
SOFIE already manufactures GE HealthCare products
The two companies already have a commercial relationship beyond FAPI research.
GE HealthCare said SOFIE already manufactures Flyrcado, its flurpiridaz F-18 injection product used for PET myocardial perfusion imaging.
SOFIE's own product information lists Flyrcado among the radiopharmaceuticals it provides, alongside other PET tracers.
The acquisition therefore brings an existing supplier relationship inside GE HealthCare rather than creating an entirely new manufacturing connection.
SOFIE will continue serving other companies
One potentially important detail is that SOFIE will not simply become a closed manufacturing operation dedicated exclusively to GE HealthCare.
GE HealthCare says SOFIE will continue operating as an independent manufacturing partner for existing customers, including companies that provide other radiopharmaceutical products.
That means GE HealthCare can acquire the infrastructure while continuing to benefit from SOFIE's role in the wider radiopharmaceutical market.
The deal fits a much bigger shift in nuclear medicine
The acquisition comes as the radiopharmaceutical industry is expanding beyond traditional diagnostic imaging.
New molecular tracers are being developed to identify specific biological targets. At the same time, related technologies are being explored for targeted treatments, an approach commonly described as theranostics.
GE HealthCare says the industry pipeline includes approximately 20 PET radiotracers and more than 30 radiotherapeutics under development.
That creates an infrastructure problem as well as a scientific opportunity. If more products reach the market, manufacturers need enough specialized facilities to produce them and enough distribution capacity to deliver them within their usable time windows.
What “theranostics” means
Theranostics combines diagnostic imaging and targeted treatment around related biological targets.
The diagnostic side can help identify or characterize a target using molecular imaging. A related therapeutic approach can then be used to deliver treatment more selectively to cells carrying that target.
This is one reason radiopharmaceutical companies are attracting increasing attention: the same molecular-targeting concept can potentially connect diagnosis, patient selection and treatment.
GE HealthCare says the SOFIE acquisition strengthens its ability to participate across the theranostics pathway, including cyclotrons, imaging technology, digital workflow tools and radiotherapeutics infrastructure.
GE HealthCare's Pharmaceutical Diagnostics business
SOFIE will join GE HealthCare's Pharmaceutical Diagnostics segment, known as PDx.
The segment provides imaging agents used alongside medical-imaging procedures. According to company materials, GE HealthCare's PDx imaging agents supported approximately 140 million procedures globally in 2025.
The SOFIE acquisition therefore extends an existing business rather than taking GE HealthCare into an unfamiliar field.
Why GE HealthCare wants more U.S. capacity
The U.S. is particularly important because PET imaging demand and the pipeline of new radiopharmaceuticals are expanding at the same time.
A distributed production network can reduce the distance between manufacturing facilities and imaging centers. That becomes increasingly important when products have short radioactive half-lives.
SOFIE's 15-site network gives GE HealthCare a larger domestic footprint immediately after closing, although the transaction still requires regulatory approval and other conditions before it can be completed.
What GE HealthCare expects financially
GE HealthCare expects the transaction to contribute positively to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year after ownership.
The company also expects SOFIE to grow at a low-double-digit rate after becoming part of GE HealthCare. These are management expectations, not guaranteed outcomes.
The timeline behind the acquisition
SOFIE licensed FAPI compounds developed by researchers associated with Heidelberg University and began advancing FAPI imaging products.
SOFIE and GE HealthCare announced a licensing agreement covering FAPI-46 and FAPI-74 development and commercialization rights.
SOFIE announced the first patient had been dosed in its Phase III FAPI-GO study focused on gastroesophageal cancers.
SOFIE expanded U.S. manufacturing of FAPI-74 and announced the first patient dosed in the FAPI-PRO Phase III study for pancreatic cancer.
GE HealthCare announced the $945 million agreement to acquire SOFIE Biosciences.
The companies expect the transaction to close, assuming required approvals and other closing conditions are satisfied.
What could change after the deal closes?
The immediate change will be ownership, but the longer-term significance is operational.
GE HealthCare will be able to combine SOFIE's U.S. manufacturing network with its existing pharmaceutical-diagnostics business and broader medical-imaging infrastructure.
That could give the company a more integrated position across several stages of the PET ecosystem: radiopharmaceutical development, manufacturing, imaging equipment and digital workflow.
The company has also said it intends to continue using other established U.S. contract manufacturing partners. That suggests the strategy is to expand capacity rather than replace the entire existing manufacturing network with SOFIE.
What investors should watch
- Regulatory approval: The $945 million transaction has not closed yet.
- FAPI-74: Phase III development still has to produce the evidence required for potential regulatory approval.
- Manufacturing scale: GE HealthCare will need to integrate SOFIE's network without disrupting existing supply.
- Demand: Growth in PET imaging and new radiopharmaceuticals will determine how valuable additional production capacity becomes.
- Financial contribution: Management expects the acquisition to become financially accretive, but actual results will depend on execution.
What the acquisition does not mean
The deal does not mean FAPI-74 is already an approved cancer diagnostic.
It also does not mean every new radiopharmaceutical will automatically become available to patients simply because GE HealthCare owns a larger manufacturing network.
Clinical development, regulatory review, manufacturing requirements and healthcare-system adoption still determine whether investigational products eventually become approved medical products.
The acquisition should therefore be viewed as an investment in infrastructure and pipeline opportunities rather than as a guarantee of future clinical outcomes.
Why this matters beyond GE HealthCare
The transaction illustrates a broader change in medical imaging.
Imaging companies are increasingly competing not only on scanners but also on the molecular agents, software, manufacturing capabilities and clinical workflows surrounding those scanners.
As precision medicine develops, the radioactive tracer can be as strategically important as the imaging machine that detects it.
That makes specialized manufacturing networks increasingly valuable—and helps explain why GE HealthCare is willing to spend nearly $1 billion to acquire one.
GE HealthCare is buying the infrastructure behind a fast-changing part of medical imaging.
The $945 million SOFIE acquisition gives GE HealthCare a 15-site U.S. manufacturing network with 21 cyclotrons, strengthens its position in PET radiopharmaceuticals and adds U.S. rights to the Phase III FAPI-74 program. The strategic opportunity is significant because PET products can be highly time-sensitive and the radiopharmaceutical pipeline is expanding. But the transaction is not yet complete, and FAPI-74 remains investigational. The real test will be whether GE HealthCare can turn SOFIE's manufacturing footprint and pipeline into sustainable growth while maintaining reliable access to time-sensitive radiopharmaceutical products.
Post a Comment
Have something to add? Share your thoughts or let us know what you think about this story.